inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 26, 1997.

A. Federal Reserve Bank of Cleveland (Jeffery Hirsch, Banking Supervisor) 1455 East Sixth Street, Cleveland, Ohio 44101–2566:

1. Community Holding Company, Inez, Kentucky; to engage in permissible savings and loan association activities, pursuant to § 225.28(b)(4) of the Board's Regulation Y, through the conversion of its wholly-owned banking subsidiary, The First National Bank of Louisa, Louisa, Kentucky, into a federal-charted stock savings bank, Inez Deposit Bank, F.S.B., Inez, Kentucky.

B. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690–1413:

1. Firstbank of Illinois Co., Springfield, Illinois; to acquire Geneva Capital Corporation, Springfield, Illinois, and thereby engage in serving as a broker in Illinois, Indiana and St. Louis, Missouri, for mortgage loans to companies engaged in operating income-producing commercial real estate, and thereby engage in extending credit and servicing loans, pursuant to § 225.28(b)(1) of the Board's Regulation Y.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102–2034:

1. Hardin County Bancshares, Inc., Savannah, Tennessee; to acquire Majors Insurance Agency, Inc., Adamsville, Tennessee, and thereby engage in general insurance agency activities in a place where its subsidiary bank has a lending office and that has a population not exceeding 5,000, pursuant to § 225.28(b)(11) of the Board's Regulation Y.

D. Federal Reserve Bank of San Francisco (Pat Marshall, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105–1579:

1. 1867 Western Financial Corporation, Stockton, California; to acquire Capital Corp of the West, Merced, California, and thereby indirectly acquire Town and Country Finance and Thrift Company, Turlock, California, and Capital West Group, Inc., Stockton, California, and thereby engage in operating an industrial loan company, pursuant to § 225.28(b)(4); in operating an industrial loan company; in providing credit life insurance, pursuant to § 225.28(b)(11) of the Board's Regulation Y; in management consulting, pursuant to § 225.28(b)(9) of the Board's Regulation Y; and in furnishing investment and financial advice, pursuant to § 225.28(b)(6) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, August 6, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–21182 Filed 8–11–97; 8:45 am]

BILLING CODE 6210–01–F

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of Comment Period for Exposure Draft on Deferral of Required Implementation Date for Cost Accounting.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. No. 92–463), as amended, the Federal Accounting Standards Advisory Board (FASAB) announces that it is publishing for review and comment an Exposure Draft entitled *Deferral of Required Implementation Date for Statement of Federal Financial Accounting Standards Number 4.* This Exposure Draft proposes for the Cost Accounting Standard (SFFAS 4) and the Revenue Standard (SFFAS 7) that the effective dates be delayed until fiscal years beginning after September 30, 1998. Comments are due by September 12.

Hard copies of the Exposure Draft are available from FASAB, 441 G St., N.W., Washington, D.C., Room 3B18. (202–512–7350). The Exposure Draft is also available on the Internet, through FASAB's home page:

http://www.financenet.gov/fasab.htm

Dated: August 6, 1997.

Wendy M. Comes,

Executive Director.

[FR Doc. 97–21222 Filed 8–11–97; 8:45 am]

BILLING CODE 1610–01–P

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of August meeting.

SUMMARY: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. No. 92–463), as amended, notice is hereby given that the Federal Accounting Standards Advisory Board will meet on Friday, August 29, 1997, from 9:00 A.M. to 4:00 P.M. in the Elmer Staats Briefing Room, room 7C13 of the General Accounting Office building, 441 G St., N.W., Washington, D.C.

The purpose of the meeting is to discuss the following items: (1) Technical corrections to Statement 6 (*Property, Plant, and Equipment*) and to Statement 8 (*Supplementary Stewardship Reporting*) and (2) *Management's Discussion and Analysis* (MD&A) Exposure Draft.

Any interested person may attend the meeting as an observer. Board discussions and reviews are open to the public.

FOR FURTHER INFORMATION CONTACT: Wendy Comes, Executive Director, 441 G St., N.W., Room 3B18, Washington, D.C. 20548, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. No. 92–463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: August 6, 1997.

Wendy M. Comes,

Executive Director.

[FR Doc. 97–21223 Filed 8–11–97; 8:45 am]

BILLING CODE 1610–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0040]

Agency Information Collection Activities; Submission for OMB Review; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the collection of information by September 11, 1997.

ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office

Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT: Margaret R. Wolff, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance.

Food Safety Survey

Under section 903(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(b)(2)), FDA is authorized to conduct research relating to foods and to conduct educational and public information programs relating to the safety of the nation's food supply. FDA is planning to conduct a consumer survey about food safety under this authority. The food safety survey will provide information about consumers' food safety awareness, knowledge, concerns, and practices. A nationally representative sample of 2,000 adults in households with telephones and cooking facilities will be selected at random and interviewed by telephone. Participation will be voluntary. Detailed information will be obtained about risk perception, perceived sources of food contamination, knowledge of particular micro-organisms, safe care label use, food handling practices, consumption of raw foods from animals, information sources, and perceived foodborne illness experience. Most of the questions asked are identical to ones asked in a 1992–1993 survey so that changes over this time period can be assessed.

FDA estimates the burden of this collection of information as follows:

ESTIMATED ANNUAL REPORTING BURDEN

No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
2,000	1	2,000	.5	1,000

There are no operating and maintenance costs or capital costs associated with this information collection.

This will be a one-time survey. The burden estimate is based on FDA's experience with the 1992–1993 survey mentioned previously.

Dated: August 6, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–21293 Filed 8–11–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA–225–97–4000]

Memorandum of Understanding Between the Food and Drug Administration and the Department of Defense

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between the FDA and the Department of Defense (DoD). The purpose of the MOU is for FDA to provide the quality assurance support for DoD centrally managed contracts for drugs, biologics, and medical devices. This MOU supersedes the agreement concerning drugs and biologics, dated December 17, 1975, and the agreement concerning devices, dated December 23, 1981.

DATES: The agreement became effective January 14, 1997.

FOR FURTHER INFORMATION CONTACT: Paul Donnelly, Medical Products Quality Assurance Staff, Office of Regulatory Affairs (HFC–240), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–0383.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and MOU's between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of an MOU.

Dated: August 5, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

Memorandum of Understanding Quality Assurance Support for Medical Products Between the Department of Defense and the Food and Drug Administration

I. Purpose

To formalize a memorandum of understanding (MOU) between the Department of Defense (DoD) and the Food and Drug Administration (FDA) whereby FDA provides the quality assurance support for DoD centrally managed contracts for drugs, biologics, and medical devices (hereinafter referred to as medical products), as defined by the Federal Food, Drug and Cosmetic Act (FDC Act), as amended, 21 U.S.C. 301 *et seq.* (1972 & Supp. 1979). This agreement supersedes the two currently effective agreements, the drug agreement dated 12/17/75 and the device agreement dated 12/23/81.

II. Background

The Office of Management and Budget (OMB) and the General Accounting Office (GAO) completed separate studies in late 1973 of nonperishable subsistence supplies. Both OMB and GAO recommended that the FDA be the agency responsible for quality assurance of all medical products procured by Federal agencies. In June 1974, the Director of OMB requested that the Department of Health, Education and Welfare (HEW) take the lead in developing an Executive Branch Plan for the government-wide quality assurance program for medical products. FDA was made responsible for developing and implementing the plan. In December 1975, FDA and DoD signed a quality assurance agreement covering drugs and biologics, and in December 1981, a corresponding agreement covering medical devices was signed. Both agreements were implemented and have been operational. However, some portions of the original agreements have become obsolete and there is a need to encompass new DoD initiatives and business practices. This updated memorandum of understanding encompasses all medical products under FDA regulatory control, and supersedes the two currently effective interagency agreements.

III. Responsibilities

A. Under the authority of DoD Directive 4140.26, the Defense Personnel Support Center (DPSC) is assigned and designated as the integrated manager for medical products. The DPSC agrees to:

(1) Furnish FDA copies of medical product quality complaints, incident reports under the Safe Medical Device Act of 1990, and other information which may impact adversely on the quality of a medical product.

(2) Provide a written request for evaluations, testing, and other work to be performed by FDA under this program.

(3) Furnish FDA copies of specifications for review, solicitations and copies of contracts requiring FDA source inspection.